TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mood and Influenza Vaccine Response: A Feasibility Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females aged 65-85 years (inclusive)~* Received influenza vaccination for the 2016/17 season~* Eligible to receive 2017/18 influenza vaccination as part of usual care~* Ability to give informed consent~Exclusion Criteria:~* Males and Females aged less than 65 or over 85 years (exclusive)~* Did not receive influenza vaccination for the 2016/17 season~* Ineligible to receive 2017/18 influenza vaccination as part of usual care~* Unable to provide informed consent~Deemed by health care provider to be:~* Too physically frail to participate~* Diagnosed with dementia or other cognitive condition which would make participation difficult~* Insufficient command of English language~* Influenza vaccination contraindicated~* Sufficiently impaired of hearing or vision that exposure to the intervention or control video content as intended would be compromised~* Those for whom the collection of blood samples is contraindicated.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Experimental (Type: EXPERIMENTAL): Participants in the experimental condition will view a video designed to induce positive affect. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
- Active Control (Type: ACTIVE_COMPARATOR): Participants in the control condition will view a video of matched length to the experimental condition video, but not designed to induce mood change. This includes short documentary clips (a pride in pencils; model railways, lecture extract on hydration), neutral music and images.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 and over~* Clinical diagnosis of cirrhosis of any cause~* Potential to benefit from HE treatment~* History of greater than or equal to 2 documented episodes of WH Grade 2 or more HE within the past 6 months, at least one of which occurred within the preceding 3 months~* No change in other HE-specific medications within 1 week before randomization~* Able to give informed consent and comply with study activities~* Availability of at least one designated family member or caregiver who is capable of and willing to assume responsibility for facilitating subject compliance with study procedures~* All females of childbearing age and all sexually active males must agree to use an acceptable method of contraception throughout the study.~Exclusion Criteria:~* Use of any investigational drug within 30 days~* Use of prohibited medications~* Uncontrolled infection~* Active GI bleeding or a history of GI bleeding requiring blood transfusion (\> 2 units) within 3 months~* Transjugular intrahepatic portosystemic shunt (TIPS) placement or revision within the past 90 days~* Recreational drug use or alcohol consumption for subjects with a history of alcohol or drug abuse within 6 months~* Lactating and/or pregnant females~* Active malignancy~* Clinically significant bowel disease, including obstruction, inflammatory bowel disease, or malabsorption~* Expected to undergo transplantation within 6 months~* Model for end-stage liver disease (MELD) score of \> 25

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HPN-100 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Misoprostol in Case of Insertion Failure of Intrauterine Contraceptives

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women aged \> 18 and \<50 years old; Requesting insertion of and IUD or an LNG-IUS Failure of IUD insertion~Exclusion Criteria:~Refuse to participate Lost to follow-up at the return visit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- misoprostol vaginal 200 mcg (Type: ACTIVE_COMPARATOR): The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
- placebo (Type: PLACEBO_COMPARATOR): The placebo group will receive two doses of placebo vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Adult subjects 18 years of age (irrespective of weight) and above at the signing of informed consent or adolescent participants ≥12 to \<18 years of age, or pediatric participants \<12 years of age at the signing of the assent (parent/guardian sign the informed consent)~2. Asymptomatic household contact with exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case). To be included in the study, participants must be randomized within 96 hours of collection of the index cases' positive SARS-COV-2 diagnostic test sample~3. Participant anticipates living in the same household with the index case until study day 29~4. Is judged by the investigator to be in good health based on medical history and physical examination at screening/baseline, including participants who are healthy or have a chronic, stable medical condition~5. Willing and able to comply with study visits and study-related procedures/assessments.~6. Provide informed consent signed by study participant or legally acceptable representative.~Key Exclusion Criteria:~1. History of prior positive SARS-CoV-2 RT-PCR test or positive SARS-CoV-2 serology test at any time before the screening~2. Participant has lived with individuals who have had previous SARS-CoV-2 infection or currently lives with individuals who have SARS-CoV-2 infection, with the exception of the index case(s), the first individual(s) known to be infected in the household~3. Active respiratory or non-respiratory symptoms consistent with COVID-19~4. History of respiratory illness with sign/symptoms of SARS-CoV-2 infection, in the opinion of the investigator, within the prior 6 months to screening~5. Nursing home resident~6. Any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the participant by their participation in the study~Note: Other protocol-defined Inclusion/ Exclusion criteria apply

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- REGN10933 + REGN10987 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Itacitinib for Low Risk GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed GVHD that meets criteria for Minnesota standard risk~* Ann Arbor 1 GVHD by biomarkers~* GVHD not previously treated systemically (topical therapies and non-absorbed steroids are allowed)~* Any donor type, HLA-match, conditioning regimen is acceptable~* Age 12 - 75 years (children \<18 years must also weigh 50 kg or more)~* Patients must be engrafted post-transplant (ANC \>500/μL and platelet count \>20,000). Use of growth factor supplementation to maintain neutrophil count is allowed.~* Direct bilirubin must be \<2 mg/dL unless the elevation is known to be due to Gilbert syndrome within 3 days prior to enrollment.~* ALT/SGPT and AST/SGOT must be \<5x the upper limit of the normal range within 3 days prior to enrollment.~* Signed and dated written informed consent obtained from patient or legal representative.~Exclusion Criteria:~* Patients currently being treated with any JAK inhibitor including ruxolitinib~* Relapsed, progressing, or persistent malignancy requiring withdrawal of systemic immune suppression~* Patients with uncontrolled infection (i.e., progressive symptoms related to infection despite treatment or persistently positive microbiological cultures despite treatment or any other evidence of severe sepsis)~* Severe organ dysfunction including requirement for dialysis, mechanical ventilation or oxygen supplementation exceeding 40% FiO2 within 7 days of enrollment.~* Creatinine clearance or estimated glomerular filtration rate \<30 ml/min as calculated by institutional practice (e.g., Cockcroft-Gault equation, CKD-EPI equation, etc)~* A clinical presentation resembling de novo chronic GVHD or overlap syndrome developing before or present at the time of enrollment~* Patients receiving corticosteroids \>10 mg/day prednisone (or other steroid equivalent) for any indication within 7 days before the onset of acute GVHD except for adrenal insufficiency or premedication for transfusions/IV meds~* Patients who are pregnant~* Patients receiving investigational agents within 30 days of enrollment. However, the Principal Investigator (PI) may approve prior use of an investigational agent if the agent is not expected to interfere with the safety or the efficacy of itacitinib~* History of allergic reaction to itacitinib or any JAK inhibitor

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Itacitinib (Type: EXPERIMENTAL): Itacitinib 200 mg administered orally daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥18 years~* Willing and able to comply with all study requirements, including scheduled visits, interventions, and laboratory tests~* Healthy adults or adults in a stable medical condition, defined as not being hospitalized within 3 months prior to the screening visit~* Subjects who have received two doses of a COVID-19 vaccine of any type between 4 to 9 months before the screening visit~Exclusion Criteria:~* Subjects with signs of active SARS-CoV-2 infection at the screening visit or within 72 hours prior to the screening visit~* Subjects who have been diagnosed with a breakthrough infection after receiving two doses of a COVID-19 vaccine~* Subjects with epilepsy or a history of febrile seizures~* Subjects who receive immunosuppressive or cytotoxic medications.~* Subjects who have a history of severe allergic reactions (e.g., anaphylaxis) to the study vaccine, any components of the study interventions, or any pharmaceutical products.~* Subjects who have received any other investigational products within 30 days prior to the screening visit or intend to participate in any other clinical studies during the period of this study.~* Subjects who have received any vaccines within 28 days prior to the screening visit or intend to receive any vaccines up to day 14 of the study.~* Subjects who have any known bleeding disorders or, in the investigator's opinion, have any contraindications for an intramuscular injection.~* Female Subjects who are pregnant or breastfeeding or have planned to become pregnant within one month after the study injection.~* Subjects who have received any blood, plasma, or immunoglobulin products from 90 days prior to the screening visit or intend to receive during the study period.~* Subjects with any condition that may increase the risk of participating in the study or may interfere with the evaluation of the primary endpoints of the study in the investigator's opinion.~* Subjects who have donated ≥450 mL of blood or blood products within 28 days prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SpikoGen COVID-19 Vaccine (Type: EXPERIMENTAL): None
- Saline Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Existence of one or more metastases of of colorectal cancer (CRC) expressing the CEA , potentially accessible by surgical or thermo resection at the moment of the diagnosis or at relapse.~OR~* Isolated and progressive elevation of plasma CEA during the monitoring of CRC with high metastatic risk~* More than 18 years~* Negative pregnancy test for women of childbearing age. Women of childbearing age should take effective continuous contraception for 3 months.~* At least 4 weeks after the last treatment and after recovery of potential toxicity~* Karnofsky more than 70 or ECOG 0-1~* Life expectancy of at least 6 months~* CEA positive immunohistochemistry or plasma CEA supperior or equal to the normal level~* Creatinin less or equal 200 micromol/L~* Signed informed consent~* geographical proximity~Exclusion Criteria:~* Pregnancy or breastfeeding~* Serious illness or comorbidity assessed risk~* History of other cancer within 5 years, with the exception of skin carcinomas other than melanomas or in-situ carcinoma of the cervix~* Anti-antibody presence in patients who have already received antibody~* Hypersensitivity to antibodies or proteins~* Intellectual inability to sign the informed consent~* Insulin-dependent diabetic patient or non-insulin dependent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TF2 antibody/68Ga-IMP-288 (Type: EXPERIMENTAL): TF2 antibody/68Ga-IMP-288

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Men or women aged 18 to 75 years,~* Historically confirmed diagnosis of ulcerative colitis by endoscopy and histology,~* Patient being in remission, defined (according to Rachmilewitz) as:~Clinical Activity Index (CAI) \<= 4, and Endoscopic Index (EI) \< 4,~* Extent of inflammation during last acute episode was \>15 cm beyond the anal margin,~* Last acute episode ended within 3 months prior to study entry.~Exclusion Criteria:~* Crohn's disease,~* Prior bowel resection leading to diarrhoea,~* Toxic megacolon,~* Gastric or duodenal ulcer,~* Haemorrhagic diathesis,~* Presence of symptomatic organic disease of the gastrointestinal tract (with the exception of haemorrhoids or hiatal hernia),~* Active colorectal cancer or a history of colorectal cancer,~* Serious other secondary illnesses of an acute or chronic nature,~* Asthma,~* Severe impairment of renal (e.g., serum creatinine \> 1.5 mg/dl) and/or liver functions (e.g., serum transaminase \[ALT and/or AST\] or alkaline phosphatase \>=2x upper limit of normal \[ULN\]),~* Application of immunosuppressants within 3 months and/or corticosteroids (oral, intravenous \[IV\] or topical rectal) within 30 days prior to baseline,~* Application of non-steroidal anti-inflammatory drugs (NSAIDs) as long term treatment (i.e. \> 6 weeks), other than acetylsalicylic acid (\<= 350 mg/day), or paracetamol,~* Known intolerance/hypersensitivity to salicylic acid and its derivatives or to any of the other constituents of the study drugs,~* Well-founded doubt about the patient's cooperation,~* Existing or intended pregnancy, breast-feeding,~* Women of child-bearing potential without adequate contraceptive protection, e.g., hormonal contraception, intrauterine device (IUD), double-barrier method of contraception (e.g., use of a condom and spermicide), partner has undergone vasectomy and subject is in monogamous relationship. The investigator is responsible for determining whether the subject has adequate birth control for study participation,~* Participation in another clinical trial within the last 30 days,simultaneous participation in another clinical trial, or previous participation in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 3.0g OD (Type: EXPERIMENTAL): None
- 1.5g OD (Type: EXPERIMENTAL): None
- 0.5g TID (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paliperidone Palmitate Flexible Dosing in Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Meet the DSM-IV criteria for schizophrenia Currently non-acute, i.e., on the same antipsychotic medication used for the treatment of schizophrenia given in an adequate dose and a CGI-S change \<= 1 in the past 4 weeks before enrollment Patient has been given an adequate dose of either an appropriate oral antipsychotic, or a protocol-defined LAI antipsychotic for an adequate period of time prior to enrollment, but current treatment is considered unsuccessful OR Patients with acute symptoms of schizophrenia, previously treated with an oral antipsychotic, having a baseline total Positive and Negative Syndrome Scale (PANSS) score \>= 80 and a baseline CGI-S score \>= 4 Women must be postmenopausal for at least 1 year, surgically sterile, abstinent (at the discretion of the investigator/per local regulations), or if sexually active, be practicing a highly effective method of birth control as local regulations permit, and before entry, must agree to continue to use the same method of contraception throughout the study Is cooperative and reliable, and agrees to receive regular injections and complete all aspects of the protocol Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.~Exclusion Criteria:~The patient's psychiatric diagnosis is due to direct pharmacological effects of a substance (e.g., a drug of abuse or medication) or a general medical condition (e.g., clinically notable hypothyroidism) First antipsychotic treatment ever, i.e., patient has never been treated with antipsychotics before and antipsychotic treatment given in this study will be the first antipsychotic treatment that the patient will have ever received On clozapine during the last 3 months Patients who remain at imminent risk of suicide even after clinical intervention Serious unstable medical condition, including recent and present clinically relevant laboratory abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paliperidone Palmitate (Type: EXPERIMENTAL): Paliperidone Palmitate 50 - 150 mg eq. every 30 days for 6 months during the core phase and for 12 months during an optional extension phase after the last patient has completed the 6-month core treatment phase or until product will be available on market (whichever comes first)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete